The rising popularity in GLP-1 agonists for metabolic conditions has led to a debate about delivery routes : skin-applied devices versus tablets . Traditionally , GLP-1 drugs were only available in pill form, but the introduction of patches provides a alternative choice . Transdermal systems migh